aTyr Pharma has received positive feedback from the U.S. Food and Drug Administration (FDA) in a meeting to discuss the regulatory development of its lead candidate, efzofitimod (ATYR1923), for the treatment of pulmonary sarcoidosis. After a review of data provided by aTyr, including results from a recently completed…
News
Horizon Therapeutics has launched its #RAREis Representation program aimed at increasing diversity, equity, and inclusion among patients with rare diseases. There are about 400 million people worldwide living with a rare disease; for many of them, access to diagnosis, care, and treatments can be challenging. Accessing better care depends on…
The Foundation for Sarcoidosis Research (FSR) is now accepting applications for fellowships supporting early career clinicians and researchers focused on sarcoidosis. The deadline is March 15, the foundation announced. The two-year grants will provide a total of $150,000 to selected fellows, with…
Bionews, the publisher of this website, hosted a virtual panel discussion on Rare Disease Day 2022, taking a deeper dive into what it’s like to live with a rare disease, including conversations about advocacy, mental health, survivor’s guilt, treatment of minority patients, and more. The Monday event, “A…
A rare disease puts an economic burden on the patients, families, and caregivers that it affects, and will no doubt be an integral part of discussions on Rare Disease Day 2022, which brings international awareness about the more than 300 million people living with rare disorders. Part of that…
The risks of death and rejection after heart transplant for people with advanced cardiac sarcoidosis were similar to those of patients who had transplants for other types of heart disease, according to an analysis of a transplant recipient registry. These findings suggest that a heart transplant is a safe…
The nonprofit RARE-X is creating an easily-accessible, centralized data hub for all rare disease patient data that can help researchers answer questions about existing disorders, discover new ones, and work toward finding treatments. It was spun out of the work that Nicole Boice, founder and chief engagement officer of…
It’s been nearly a year since the EveryLife Foundation for Rare Diseases released its expansive report finding the total economic burden of rare disorders in the U.S. to be nearly $1 trillion.
The Foundation for Sarcoidosis Research (FSR) has introduced a new online support group for those with chronic sarcoidosis. The peer-led group, created in response to patient feedback received last year, opens with a six-month schedule that began this month. Patients and caregivers can participate each month in one…
Poorer lung function and a higher body mass index (BMI), a measure indicating obesity, are significantly associated with a lower self-reported quality of life in people with sarcoidosis, a German study found. Of note, the tool used to assess quality of life — called the King’s Sarcoidosis Questionnaire or…
Recent Posts
- Kaleidoscope sparks new Sarcoidosis Awareness Month campaign
- Using our role as ‘professional patients’ to learn and pay it forward
- Most deaths in hospitalized sarcoidosis patients linked to other causes
- A night of nostalgia proves compassion counts with chronic illness
- 2 factors linked to higher risk of death for lung sarcoidosis patients in study
- Autoimmune diseases tied to higher sarcoidosis risk, new study finds
- Atyr to discuss efzofitimod’s future with FDA after Phase 3 sarcoidosis trial
- How do you celebrate Autoimmune Awareness Month?
- New congressional caucus to advocate for sarcoidosis research, funding
- Free virtual conference aims to empower sarcoidosis community